New scan could spot hidden breast cancer spread

NCT ID NCT06335069

Recruiting now Diagnosis Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two PET scan tracers—standard 18F-FDG and newer 68Ga-FAPI-46—in 20 women with ER-positive breast cancer. The goal is to see if the new tracer finds more cancer lesions, especially where the standard one may miss them. Better detection could lead to more accurate staging and tailored treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPI-46 (a radioactive tracer for PET scans)
What this could lead to: If 68Ga-FAPI-46 proves more sensitive, it could improve staging accuracy for ER+ breast cancer, leading to better treatment decisions.
What could go wrong: This is a small pilot study with only 20 participants, so results may not apply broadly. The new tracer may not detect more lesions than the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast disorder breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST DISEASES BREAST NEOPLASMS

Contacts and locations

Locations

Maastricht University Medical Center+
RECRUITING

Maastricht, 5800, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.